NEW YORK (GenomeWeb) – T2 Biosystems announced today that it has signed a multi-year deal giving Bayer access to its T2 Magnetic Resonance (T2MR) technology platform for use in its R&D efforts in blood coagulation disorders.

Under the terms of the deal, the companies will use the technology to develop tools and evaluate assays for drug discovery and biomarker research in certain Bayer hemostasis-related programs.

Additional terms were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The Atlantic reports that genetic counselors are coping with an influx of patients seeking advice on their direct-to-consumer genetic test results.

A small study finds differences between three genomic prostate cancer tests, Medscape reports.

In Nature this week: shared genetic architecture for asthma and allergic diseases, and more.

A survey of Canadians finds them to be divided on genetically modified food, the Ottawa Citizen reports.